Gefitinib and Methotrexate to Treat Ectopic Pregnancies with a Pre-Treatment Serum hCG 1000–10,000 IU/L : Phase II Open Label, Single Arm Multi-Centre Trial

Skubisz, Monika M.Tong, StephenDoust, AnnMollison, JillJohns, Terrance G.Neil, PeterRobinson, MirandaBhattacharya, SiladityaWallace, EuanKrzys, NicoleColin Duncan, W.Horne, Andrew W.2018-07-302018-07-302018-07Skubisz, M M, Tong, S, Doust, A, Mollison, J, Johns, T G, Neil, P, Robinson, M, Bhattacharya, S, Wallace, E, Krzys, N, Colin Duncan, W & Horne, A W 2018, 'Gefitinib and Methotrexate to Treat Ectopic Pregnancies with a Pre-Treatment Serum hCG 1000–10,000 IU/L : Phase II Open Label, Single Arm Multi-Centre Trial', EBioMedicine, vol. 33, pp. 276-281. https://doi.org/10.1016/j.ebiom.2018.06.0172352-3964ORCID: /0000-0002-4588-356X/work/159509575http://hdl.handle.net/2164/10826This work was supported by an NHMRC Grant (#1008276) to ST, TJ and EW, and an MRC Centenary Award (G0802808) to AH. The funders had no role study design, collection, analysis, and interpretation of data; in the writing of the report or in the decision to submit the paper.6602597engSDG 3 - Good Health and Well-beingEctopic pregnancyGefitinibMedical treatmentMethotrexatePhase IIR MedicineGeneral Biochemistry,Genetics and Molecular BiologyMedical Research Council (MRC)G0802808RGefitinib and Methotrexate to Treat Ectopic Pregnancies with a Pre-Treatment Serum hCG 1000–10,000 IU/L : Phase II Open Label, Single Arm Multi-Centre TrialJournal article10.1016/j.ebiom.2018.06.017http://www.scopus.com/inward/record.url?scp=85048938616&partnerID=8YFLogxK33